Senhwa Biosciences raises $16M to advance AI-powered drug discovery, accelerate cancer treatment trials, and expand machine learning platforms globally.

The U.S. Food and Drug Administration (FDA) has granted plixorafenib a Breakthrough Therapy Designation, signaling accelerated development of this targeted drug for patients with an aggressive high-grade glioma (a cancerous brain tumor) harboring a mutated BRAF protein.

By Bhanvi Satija LONDON, April 12 (Reuters) - British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped shrink tumors in patients with advanced,

Adcendo secures $75M Series C funding to advance innovative cancer therapies and expand its antibody-drug conjugate pipeline.

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall response rate in a Phase 2 trial.

The new data bolster Allogene’s efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.

SHANGHAI, April 10 (Reuters) - Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines said on Friday on WeChat.

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually develop drug resistance, leaving doctors desperate for ...

Pembro, made by pharma giant MSD, is hailed as a drug that saves and prolongs lives but it comes at an exorbitant cost